

# Paul Coplan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10709241/publications.pdf>

Version: 2024-02-01

9  
papers

504  
citations

1163117  
8  
h-index

1474206  
9  
g-index

9  
all docs

9  
docs citations

9  
times ranked

418  
citing authors

#	ARTICLE	IF	CITATIONS
1	Postmarketing evaluation of the safety and effectiveness of varicella vaccine. <i>Pediatric Infectious Disease Journal</i> , 1999, 18, 1041-1046.	2.0	114
2	Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women. <i>Aids</i> , 2009, 23, 1531-1538.	2.2	77
3	Pharmacokinetic Assessment of Dapivirine Vaginal Microbicide Gel in Healthy, HIV-Negative Women. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 1181-1190.	1.1	70
4	Perceptions of Sexual Behavior and Knowledge About Sexually Transmitted Diseases Among Adolescents in Benin City, Nigeria. <i>International Perspectives on Sexual and Reproductive Health</i> , 1999, 25, 186.	1.1	57
5	Impact of an intervention to improve treatment-seeking behavior and prevent sexually transmitted diseases among Nigerian youths. <i>International Journal of Infectious Diseases</i> , 2003, 7, 61-73.	3.3	55
6	Incidence and hospitalization rates of varicella and herpes zoster before varicella vaccine introduction: a baseline assessment of the shifting epidemiology of varicella disease. <i>Pediatric Infectious Disease Journal</i> , 2001, 20, 641-645.	2.0	50
7	A post-licensure evaluation of the safety of inactivated hepatitis A vaccine (VAQTA® <sup>®</sup> , Merck) in children and adults. <i>Vaccine</i> , 2004, 22, 766-772.	3.8	40
8	Is HIV drug resistance a limiting factor in the development of anti-HIV NNRTI and NRTI-based vaginal microbicide strategies?. <i>Antiviral Research</i> , 2006, 71, 343-350.	4.1	33
9	Post-marketing evaluation of the short term safety of COMVAX® <sup>®</sup> . <i>Vaccine</i> , 2004, 22, 536-543.	3.8	8